- Senior Investigator, Department of Laboratory Medicine
Dr. Fleisher received his medical and pediatric training at the University of Minnesota and went on for training in immunology at NIH in the laboratory of Dr. Thomas Waldmann. Following this training and a brief faculty position at Walter Reed Army Medical Center, he was chosen to direct the Clinical Immunology Laboratory in the Department of Laboratory Medicine at NIH. In 1998, he was selected as chief of the Department of Laboratory Medicine, where he also continues to run the Immunology Service within the department. He is an adjunct professor of pediatrics at Uniformed Services University of the Health Sciences, and serves as consultant to the Allergy Immunology Department at Walter Reed Military Medical Center. He served as a member of the board of directors of the American Board of Allergy and Immunology from 1991-2000 and was elected chair of the board in 1996. He also was a member of the American Board of Pediatrics from 1996-2001; the executive committee of the Clinical Immunology Society from 2003-2006, serving as its president in 2005; and the board of directors of the American Academy of Allergy, Asthma and Immunology from 2003-2007. He was President of the Robert A. Good Immunology Society from 2008-2010 and currently is a member of the Section on Allergy and Immunology Executive Committee of the American Academy of Pediatrics.
- (2020). Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Introduction. Journal of Allergy and Clinical Immunology-In Practice. 8(9), S1-S2.
- (2020). A Nonsense N -Terminus NFKB2 Mutation Leading to Haploinsufficiency in a Patient with a Predominantly Antibody Deficiency (vol 82, pg 613, 2020). JOURNAL OF CLINICAL IMMUNOLOGY. 40(8), 1102-1102.
- (2020). A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia. AMERICAN JOURNAL OF HEMATOLOGY. 95(11), E310-E313.
- (2020). A Nonsense N -Terminus NFKB2 Mutation Leading to Haploinsufficiency in a Patient with a Predominantly Antibody Deficiency. JOURNAL OF CLINICAL IMMUNOLOGY. 40(8), 1093-1101.
- (2020). Y-90-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 35(4), 249-261.